Outlook Therapeutics, Inc. (OTLK): Depreciation & Amortization
$117.1K
Year ended 2025-09-30
$104.0K
Trailing 12 months to 2026-06-30
-17.0%
3-year compound annual growth
-26.7%
5-year compound annual growth
-24.0%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $117.1K | +2.8% | 2025-12-19, From 2024-10-01 |
| 2024-09-30 | $113.9K | +157.7% | 2025-12-19, From 2023-10-01 |
| 2023-09-30 | $44.2K | -78.4% | 2024-12-27, From 2022-10-01 |
| 2022-09-30 | $204.7K | -21.9% | 2023-12-22, From 2021-10-01 |
| 2021-09-30 | $262.1K | -52.7% | 2022-12-29, From 2020-10-01 |
| 2020-09-30 | $554.1K | -83.5% | 2021-12-23, From 2019-10-01 |
| 2019-09-30 | $3.36M | +10.1% | 2020-12-23, From 2018-10-01 |
| 2018-09-30 | $3.05M | +13.5% | 2019-12-19, From 2017-10-01 |
| 2017-09-30 | $2.69M | +12.4% | 2018-12-18, From 2016-10-01 |
| 2016-09-30 | $2.39M | +31.2% | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | $1.82M | n/a | 2016-12-29, From 2014-10-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $117.1K | +2.8% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.42M | -13.8% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $2.48M | +8.7% |
| Pluri Inc. (PLUR) | 2026-06-30 | $511.0K | +61.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $6.58M | +21.0% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $400.0K | -63.6% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $364.0K | -9.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $537.0K | -62.8% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $19.48M | +1.1% |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗